Eupraxia Pharmaceuticals (EPRX) Other Operating Expenses (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has reported Other Operating Expenses for 4 consecutive years, with -$1.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Operating Expenses fell 180333.49% year-over-year to -$1.9 million; the TTM figure through Mar 2026 stood at -$1.9 million (down 521.98% YoY), while the FY2024 annual figure was $18611.0, up 484.05% from the prior year.
• Other Operating Expenses slipped to -$1.9 million in Q1 2026 per EPRX's latest filing, from -$1075.0 in the prior quarter.
• Across five years, Other Operating Expenses topped out at $2.1 million in Q4 2023 and bottomed at -$3.7 million in Q2 2023.
• Historically, Other Operating Expenses has averaged -$64907.8 across 4 years, with a median of $2150.0 in 2025.
• Annual changes were most pronounced in 2024 — Other Operating Expenses soared 345.17% — and 2026, when it plunged 180333.49%.
• Eupraxia Pharmaceuticals' Other Operating Expenses stood at $2.1 million in 2023, then tumbled by 98.56% to $29979.0 in 2024, then plunged by 103.59% to -$1075.0 in 2025, then plunged by 180333.49% to -$1.9 million in 2026.
• Business Quant data shows EPRX's Other Operating Expenses at -$1.9 million in Q1 2026, -$1075.0 in Q4 2025, and $2150.0 in Q2 2025.